about
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNAA large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human gliomaNon-coding RNAs: a key to future personalized molecular therapy?Reprogramming of miRNA networks in cancer and leukemia.A miRNA signature for defining aggressive phenotype and prognosis in gliomas.Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesisPluripotent stem cell miRNAs and metastasis in invasive breast cancer.miRNA signatures associate with pathogenesis and progression of osteosarcoma.miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse modelAssociation between idiopathic hearing loss and mitochondrial DNA mutations: a study on 169 hearing-impaired subjects.Profiling of the Predicted Circular RNAs in Ductal In Situ and Invasive Breast Cancer: A Pilot StudyMicroRNA expression signatures in solid malignancies.Next generation analysis of breast cancer genomes for precision medicine.miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease.miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cellsRisk factors associated with relapse of eyelid basal cell carcinoma: results from a retrospective study of 142 patients.Identification of microRNA activity by Targets' Reverse EXpression.GAMES identifies and annotates mutations in next-generation sequencing projects.A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants.An Ultraconserved Element Containing lncRNA Preserves Transcriptional Dynamics and Maintains ESC Self-Renewal.Loss of miR-204 expression is a key event in melanoma.Prion proteins (PRNP and PRND) are over-expressed in osteosarcoma
P50
Q28259224-7F2F82BE-4C4A-4521-92A6-FCF9493C66A2Q28654361-F2567758-C0BA-4A0C-9F6F-5D490C15B8AEQ33762263-9FD0F30B-7D61-421F-BB6B-B52A1FF0E080Q33812540-85A81DF0-ABD0-49FF-AD31-87E80D2A9311Q34287223-2E92E9D4-6AEF-4B00-B06A-9A9292C9D5DAQ34334539-F04A06A8-A73E-4D17-8EC1-3234A113DEB7Q35102562-62274057-3907-45FE-9140-9E587D4A1FE8Q35894610-70529812-E58D-473B-A8B1-FE4CBD86ADE7Q36471327-2EC93372-E8CF-46E6-98D7-A5E4A6BBBEEAQ37265644-38F040F9-B3BC-43D6-8610-FE2C926CB3CEQ37443648-07A71BA1-B459-4B97-B4BA-9C9A929214EDQ38014606-14D6A1E8-C46C-4314-8585-5A5F93E9847BQ38123573-3EB75162-139B-43A4-A6D6-F92C5C3D6DD2Q38816532-BD5BA2A1-2F14-4F7B-82A2-B3E76D0F29C4Q38845409-21EFBF51-353F-4356-98E5-2F177C3D5355Q38902516-4CC86405-6914-40B2-9FA1-C7D1C7B6DFA3Q42509925-1D49D33D-54B6-49A9-AFC4-8A470C201E80Q42949265-2A5C1084-0D7E-42DD-A920-51186E25DBB0Q43649041-164DCD6F-769B-4B27-8DAF-D398E4EDED5BQ47192998-B3D2C63E-B451-46C2-A489-918C27C7D366Q49886500-97B37588-0FF2-4730-AF75-916E1343479DQ51734980-1BFB3E0B-FEFC-46C8-B88B-3CDD3A1B8867Q57200251-A9AD7854-AE4B-4317-AEE7-86372127596F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Galasso
@ast
Marco Galasso
@en
Marco Galasso
@es
Marco Galasso
@nl
type
label
Marco Galasso
@ast
Marco Galasso
@en
Marco Galasso
@es
Marco Galasso
@nl
prefLabel
Marco Galasso
@ast
Marco Galasso
@en
Marco Galasso
@es
Marco Galasso
@nl
P106
P1153
35333987800
P21
P31
P496
0000-0003-2655-4792